Sebia announced the acquisition of Zeus Scientific, an in vitro diagnostic (IVD) company based in New Jersey (US) specializing in autoimmune and infectious diseases technologies. Financial terms of the agreement are undisclosed. The state-of-the-art diagnostic company, Zeus Scientific, will provide synergies and expand Sebia’s capabilities and product portfolio in autoimmunity, with a strong footprint in the United States. Zeus Scientific is a global company focusing on the development, production and marketing of in vitro diagnostic tests to detect autoimmune and infectious diseases, available in several different technology applications. Clinical areas include inflammatory rheumatic diseases, serological detection of autoimmune vasculitis, thyroid diagnostics, gastroenterology and a number of infectious diseases, with a strong focus on Lyme disease.
70% of medical decisions are based on laboratory test results, including in vitro diagnostic tests. The global in vitro diagnostics market is projected to reach $113.1 billion by 2026 at a CAGR of 2.9%. The autoimmune disease diagnostics market was valued at around $1.1 billion in 2021 and is estimated to register over 6.6% CAGR between 2022 and 2030.
